Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,041.30 -31.99 (-2.98%)
Streaming Delayed Price Updated: 9:52 AM EST, Jan 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly ↗
Via Stocktwits
News headline image
The Silicon Laureates: How 2024’s ‘Nobel Prize Moment’ Rewrote the Laws of Scientific Discovery
The history of science is often measured in centuries, yet in October 2024, the timeline of human achievement underwent a tectonic shift that is only now being fully understood in early 2026. By... 
Via TokenRing AI
Topics Artificial Intelligence Electric Vehicles
News headline image
Behind the Scenes of Eli Lilly and Co&#39;s Latest Options Trends ↗
 
Via Benzinga
News headline image
The Digital Microscope: How AlphaFold 3 is Decoding the Molecular Language of Life
As of January 2026, the landscape of biological research has been irrevocably altered by the maturation of AlphaFold 3, the latest generative AI milestone from Alphabet Inc. (NASDAQ: GOOGL). Developed... 
Via TokenRing AI
Topics Artificial Intelligence Bonds
FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warnings ↗
Via Stocktwits
News headline image
Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief ↗
Retatrutide is an exciting GLP-1 drug that has explosive potential. 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Gained 39.2% In 2025 ↗
The company is benefiting mightily from its portfolio of weight-loss drugs. 
Via The Motley Fool
Slimmer Waistlines, Fatter Margins: Jefferies Says Airline Companies Will Profit From America’s Weight-Loss Boom ↗
Via Stocktwits
News headline image
Healthcare Sector Stages Resilient Rebound as Policy Clarity and GLP-1 Innovations Fuel Investor Optimism
The U.S. healthcare sector has entered 2026 on a remarkably strong footing, staging a decisive rebound after a tumultuous 2025. This resurgence is being driven by a rare alignment of legislative... 
Via MarketMinute
Topics Earnings Economy
Eli Lilly & Co (NYSE:LLY) Combines High Growth Momentum with a Strong Technical Setup ↗
Via Chartmill
News headline image
The Great Tariff-Inflation Tug-of-War: Why the Fed’s 2% Target Remains Elusive in 2026
As the United States enters the first quarter of 2026, the global economy is grappling with a radical shift in trade dynamics that has upended decades of globalization. The aggressive... 
Via MarketMinute
Topics Economy Supply Chain World Trade
News headline image
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗
Plenty of growth lies ahead for these top healthcare companies. 
Via The Motley Fool
News headline image
A Fresh IPO That Long-Term Investors Shouldn’t Ignore ↗
Via MarketBeat
Topics Initial Public Offering
News headline image
Is It Time to Dump Your Shares of Eli Lilly? ↗
What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Jim Cramer Calls Nvidia, Eli Lilly Partnership &#39;Monumental Effort&#39; To &#39;Speed Up&#39; Critical Drug Creation ↗
Jim Cramer calls Nvidia-Eli Lilly partnership a "monumental effort" to speed up drug creation, despite Wall Street ignoring major AI shift. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns ↗
Via MarketBeat
News headline image
Why This Fund Made a $72 Million Bet on a Stock Headed for a $210 Per Share Takeout ↗
Chart Industries delivers engineered cryogenic and heat transfer equipment to energy and industrial gas markets worldwide. 
Via The Motley Fool
Topics Supply Chain
News headline image
The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound
For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance
Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds ↗
NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial intelligence across research, clinical trials, and supply chains over the next five... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? ↗
Both companies now aim to win in the oral weight loss drug market. 
Via The Motley Fool
News headline image
Cooling Inflation Ignites Market Optimism: December CPI Report Paves Way for Fed Pivot
The Bureau of Labor Statistics released the December 2025 Consumer Price Index (CPI) report on the morning of January 13, 2026, revealing a headline inflation rate of 2.7%. While the headline figure... 
Via MarketMinute
Topics Artificial Intelligence Bonds Credit Cards
News headline image
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? ↗
The gap may be too hard to close in the next 12 months. 
Via The Motley Fool
News headline image
What to Expect From Eli Lilly’s Q4 2025 Earnings Report
Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits. 
Via Barchart.com
News headline image
Is the Vanguard Dividend Appreciation ETF a Buy Now? ↗
This Vanguard ETF could be appealing to investors seeking both growth and income. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Why Tempus AI Stock Rose Today ↗
The data provider's artificial intelligence-driven solutions are accelerating drug discovery. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security
On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
This NVIDIA Partnership Shows How Big AI Can Really Get ↗
Via MarketBeat
Topics Artificial Intelligence
News headline image
Nvidia Stock Continues To Crawl But Analysts See Strong Upside Ahead ↗
Nvidia said on Monday that it will partner with Eli Lilly to fund a new artificial intelligence research lab, committing up to $1 billion over five years. 
Via Talk Markets
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.